Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-07

Clinical Trial Update: Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating five doses of RPL554 versus placebo in COPD patients via a dry powder inhaler has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RPL554 (RPL554)

Snippet

Sponsor: Verona Pharma plc | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2021-05-07